2019
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
BECKER D, IYENGAR A, PUNEKAR S, NG J, ZAMAN A, LOEB S, BECKER K, MAKAROV D. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Research 2019, 39: 2467-2473. PMID: 31092441, DOI: 10.21873/anticanres.13366.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAbi/enzaCastration-resistant prostate cancerPSA progressionEnd of lifeProstate cancerVeterans AffairsOlder patientsBlack patientsClinical benefitClinical endpointsHospice servicesNational guidelinesPatientsEnza treatmentAdditional studiesProgressionENZAAbirateroneRegression analysisCancerTreatmentABIEnzalutamideEndpoint
2012
Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma
Friedberg J, Culligan M, Mick R, Stevenson J, Hahn S, Sterman D, Punekar S, Glatstein E, Cengel K. Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. The Annals Of Thoracic Surgery 2012, 93: 1658-1667. PMID: 22541196, PMCID: PMC4394024, DOI: 10.1016/j.athoracsur.2012.02.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunohistochemistryIntraoperative CareMaleMesotheliomaMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPhotochemotherapyPleuraPleural NeoplasmsRisk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsProgression-free survivalMacroscopic complete resectionRadical pleurectomyIntraoperative photodynamic therapyNonepithelial subtypeMedian survivalComplete resectionEpithelial subtypesStage III/IV diseaseMedian progression-free survivalStage III/IV cancerPhotodynamic therapyLung-sparing approachLung-sparing surgeryMalignant pleural mesotheliomaPostoperative mortalitySystemic therapyPleural mesotheliomaEpithelial diseasePatientsMesotheliomaSubtypesTherapyMonthsSurvival